InvestorNewsBreaks – Retension Pharmaceuticals, Inc. (NASDAQ: RTSN) Prices Upsized $45 Million Initial Public Offering
Retension (NASDAQ: RTSN), a clinical-stage biopharmaceutical company developing treatments for hypertension and other cardiovascular diseases, announced the pricing of its upsized initial public offering of 3,750,000 shares of common stock at $12 per share, generating expected gross proceeds of $45 million before underwriting discounts, commissions and other offering expenses. The company granted underwriters a 30-day option to purchase up to an additional 562,500 shares. Retension…